EC Number   |
Application |
Reference |
|---|
   1.5.1.33 | drug development |
target for antifolate chemotherapy against Leishmania |
686614 |
| 1.5.1.33 | drug development |
target for antiparasite drug development |
689793 |
| 1.5.1.33 | drug development |
the classical antifolates targeting dihydrofolate reductase (DHFR) are ineffective towards trypanosomatid parasites owing to a metabolic bypass by the expression of pteridine reductase 1 (PTR1). The combined inhibition of PTR1 and DHFR activities in Trypanosoma parasites represents a promising strategy for the development of new effective treatments for human African trypanosomiasis (HAT) |
763844 |
| 1.5.1.33 | drug development |
the enzyme is considered a promising target for anti-leishmanial drug development and several inhibitors that share the substrate scaffold |
742445 |
| 1.5.1.33 | medicine |
enzyme is a target for development of improved therapies for infection by trypanosomatid parasites |
654109 |
| 1.5.1.33 | medicine |
enzyme is an important chemotherapeutic target for drugs against Leishmania |
657281 |
| 1.5.1.33 | pharmacology |
successful antifolate chemotherapy in Leishmania will have to target simultaneously both pterine reductase 1 and dihydrofolate reductase-thymidylate synthase |
484952, 484953 |
